IGF-I (1-3) is a minimal N-terminal tripeptide of insulin-like growth factor I. The short motif is useful in examining initial receptor contact determinants and local charge distribution. Researchers employ it in binding studies, fragmentation mapping, and structure-based design. Its simplicity enables precise analytical and computational modeling.
CAT No: I01002
Synonyms/Alias:Gly-pro-glu; Glycyl-prolyl-glutamic acid; 32302-76-4; Glypromate; glycyl-l-prolyl-l-glutamic acid; ZYK4RVV5LS; (2S)-2-[[(2S)-1-(2-aminoacetyl)pyrrolidine-2-carbonyl]amino]pentanedioic acid; IGF-I (1-3); MFCD00144405; UNII-ZYK4RVV5LS; CHEMBL371315; SCHEMBL1170125; DTXSID80186038; CHEBI:163960; L-Glutamic acid, glycyl-L-prolyl-; Gly-Pro-Glu, >=98% (HPLC); (1-3)IGF-1; DB05633; DA-53632; HY-117483; L-Glutamic acid, N-(1-glycyl-L-prolyl)-; CS-0066182; NS00069173; (1-3)-HUMAN INSULIN-LIKE GROWTH FACTOR I; BRD-K83502127-001-01-6
1. An Open-label, Single-center, Safety and Efficacy Study of Eyelash Polygrowth Factor Serum
4. Low bone turnover and low BMD in Down syndrome: effect of intermittent PTH treatment
5. C-Peptide replacement therapy and sensory nerve function in type 1 diabetic neuropathy
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.
Read More